(3R,4aR,13bR)-3-(2-Methyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol

(3R,4aR,13bR)-3-(2-Methyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isochinolin-3-ol

(3R,4aR,13bR)-3-(2-Méthyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinoléin-3-ol

(3R,4aR,13bR)-3-(2-Methyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol

1H-Benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3R,4aR,13bR)-

36504-93-5

A7A2802VNL

rel-(3R,4aR,13bR)-3-(1,1-Dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol

(+)-butaclamol

(1R,6R,8R)-6-tert-butyl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol

(3R,4aR,13bR)-3-tert-butyl-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol

(3R-(3alpha,4aalpha,13bbeta))-3-(1,1-Dimethylethyl)-2,3,4,4a,8,9,13b,14-ocahydro-1H-benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinoline-3-ol

(−)-Butaclamol

1H-Benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-ocahydro-, (3R-(3alpha,4aalpha,13bbeta))-

36504-93-5 (free base)

3alpha-tert-Butyl-2,3,4,4abeta,8,9,13balpha,14-octahydro-1H-benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol

51152-91-1

56245-67-1

Butaclamol

Butaclamol free base

Butaclamol, (−)-

Butaclamol, l-

Butaclamolum

D(1A) dopamine receptor

d-Butaclamol

DRD1_HUMAN

l-Butaclamol

PDSP1_000856

PDSP2_000761

PDSP2_000843

PDSP2_001302